GSK CEO Emma Walmsley gave an upbeat assessment of the British drugmaker's new respiratory syncytial virus (RSV) vaccine on ...
Preventive treatment is now available for the respiratory syncytial virus, which affects 64 million people annually. But drug ...
As the battle between new respiratory syncytial virus (RSV) vaccines heats up, GSK is “delighted” with the progress it's made ...
The AstraZeneca office building in Brussels, Friday, Jan. 29, 2021. Amid a dispute over expected shortfalls, the European Union is looking at legal ways to guarantee the delivery of all the COVID-19 ...
RSV vaccines are dwindling as cases continue to rise. Here's what you need to know about the RSV vaccine shortage and how you ...
Of the roughly 14,000 doses requested by CT, only about 10,000 have been received and distributed, CT public health officials ...
US health authorities on Thursday approved the world's first vaccine for chikungunya, a virus spread by infected mosquitoes that the Food and Drug Administration called "an emerging global health ...
A first of its kind vaccine has been approved by the FDA to prevent infections with the chikungunya virus. The virus is most prevalent in semi-tropical and tropical areas, such as Central and ...
The tools to combat mosquito-linked illnesses received a shot in the arm with the United States Food and Drug Administration approving Ixchiq, the first chikungunya vaccine. Ixchiq from French ...
LONDON (Reuters) -GSK CEO Emma Walmsley said on Thursday that the British drugmaker's respiratory syncytial virus (RSV) vaccine was now expected to generate more than 1 billion pounds ($1.26 billion) ...
Nov. 10, 2023 -- The FDA on Thursday approved the first vaccine for the chikungunya virus, which is transmitted to humans through mosquito bites. The vaccine, called Ixchiq and produced by Valneva ...
